A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 10, 2019

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Waldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia Refractory
Interventions
DRUG

ICP-022

ICP-022 at a dose of 150mg PO QD

Trial Locations (16)

100000

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

Unknown

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei

West China hospital of sichuan university, Sichuan

Union Hospital affiliated to Fujian Medical University, Fuzhou

The First Affiliated Hospital of Xiamen University, Xiamen

First Affiliated Hospital of Zhengzhou University, Zhengzhou

Henan Cancer Hospital, Zhengzhou

Henan Provincial Peoples's Hospital, Zhengzhou

Tongji Hospital affiliated to Huazhong University of Science and Technology, Wuhan

Jiangsu Province Hospital, Nanjing

The First Affiliated Hospital of Soochow University, Suzhou

Shengjing Hospital of China Medical University, Shenyang

Ruijin Hospital affiliated to Shanghai Jiao Tong University, Shanghai

Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin

Union Hospital affiliated to Huazhong University of Science and Technology, Hubei

The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT04440059 - A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia | Biotech Hunter | Biotech Hunter